The Valley Desk

NCT03924895 · Interventional trial

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Overall registry status Active not recruiting

Phase 3

Conditions Urinary Bladder Cancer, Muscle-invasive

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov